scholarly journals Tracing all patients who received insured dialysis treatment in Japan and the present situation of their number of deaths

2022 ◽  
Author(s):  
Shinichiro Kubo ◽  
Tatsuya Noda ◽  
Tomoya Myojin ◽  
Yuichi Nishioka ◽  
Saho Kanno ◽  
...  
Keyword(s):  
Survival Rate ◽  
Dialysis Initiation ◽  
Cumulative Survival Rate ◽  
National Database ◽  
Dialysis Patients ◽  
Cumulative Survival ◽  
Data Registry ◽  
Japanese Residents ◽  
Concomitant Medications ◽  
Definition Of

Abstract Background The survival rate of chronic dialysis patients in Japan remains the highest worldwide, so there is value in presenting Japan’s situation internationally. We examined whether aggregate figures on dialysis patients in the National Database of Health Insurance Claims and Special Health Checkups of Japan (NDB), which contains data on insured procedures of approximately 100 million Japanese residents, complement corresponding figures in the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR). Methods Subjects were patients with medical fee points for dialysis recorded in the NDB during 2014–2018. We analyzed annual numbers of dialysis cases, newly initiated dialysis cases– and deaths. Results Compared with the JRDR, the NDB had about 6–7% fewer dialysis cases but a similar number of newly initiated dialysis cases. In the NDB, the number of deaths was about 6–10% lower, and the number of hemodialysis cases was lower, while that of peritoneal dialysis cases was higher. The cumulative survival rate at dialysis initiation was approximately 6 percentage points lower in the NDB than in the JRDR, indicating that some patients die at dialysis initiation. Cumulative survival rate by age group was roughly the same between the NDB and JRDR in both sexes. Conclusion The use of the NDB enabled us to aggregate data of dialysis patients. With the definition of dialysis patients used in this study, analyses of concomitant medications, comorbidities, surgeries, and therapies will become possible, which will be useful in many future studies.

scholarly journals Observation of Stereotactic Radiosurgery (Cyberknife) on Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

2018 ◽  
Vol 2 (4) ◽  
Author(s):  
Yang Tang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Rate ◽  
Portal Vein ◽  
Stereotactic Radiosurgery ◽  
Cox Proportional Hazards Model ◽  
Cumulative Survival Rate ◽  
Portal Vein Tumor Thrombosis ◽  
Cumulative Survival ◽  
Tumor Thrombosis ◽  
Stable Conditions

The purpose of the study was to analyze the clinical effect of stereotactic radiosurgery (SRS) (Cyberknife) on hepatocellular carcinoma with portal vein tumor thrombosis (HCC-PVTT). Data from 50 patients with HCC-PVTT who received Cyberknife from August 2013 to April 2016 was collected for efficacy analysis. Moreover, survival correlation was evaluated by Cox proportionalhazards model. The total effective rate in 1–3 months after treatment was 64.00%, including 7 cases in complete remission, 12 cases in partial remission, 13 cases in stable conditions, and 18 cases with enlargement; a 4–24-months follow-up (with an average of 11.58 ± 2.58 months) showed that median survival, 1-year cumulative survival rate, and 2-year cumulative survival rate were, respectively, 11.86 ± 1.79 months, 48.00%, and 20.00%. Moreover, the Cox proportional-hazards model indicates that it was with no correlation between lesion diameter, classification of liver function, pre-operative alphafetoprotein, types of hepatitis, number of tumors, ascites, types of tumor emboli, total dose, and survival rate. SRS is effective for HCC-PVTT and serves as an ideal treatment clinically to help preserve patients’ lives, which is worthy of clinical promotion and application.

scholarly journals Geriatric scores can predict long-term survival rate after hip fracture surgery

2019 ◽  
Author(s):  
Carmen da Casa ◽  
Carmen Pablos-Hernández ◽  
Alfonso González-Ramírez ◽  
José Miguel Julián-Enriquez ◽  
Juan F Blanco
Keyword(s):  
Hip Fracture ◽  
Survival Rate ◽  
Barthel Index ◽  
Charlson Index ◽  
Cumulative Survival Rate ◽  
Term Survival ◽  
Cumulative Survival ◽  
Hip Fracture Surgery ◽  
Katz Index ◽  
Fracture Surgery

Abstract Background: The management of hip fractures is nowadays mainly performed in Orthogeriatric Units, one of whose fundamental tools is the application of geriatric scores. The purpose of this study is to establish the potential usefulness of Barthel Index, Katz Index, Lawton-Brody Index and Physical Red Cross Scale geriatric scores as predictors of survival rate and readmission rate in older patients after hip fracture surgery. Methods: We designed a prospective single-center observational study, including 207 older adults over age 65 who underwent hip fracture surgery in the first half of 2014 and followed up to September 2018. Cumulative survival and readmission rates were analyzed by Kaplan-Meier; group comparison, by Log-Rank and hazard ratio, by Cox regression. Results: We found statistical differences (p<0.001) for cumulative survival rate by every geriatric score analyzed (BI HR=0.98 [0.97,0.99]; KI HR=1.24 [1.13-1.37]; LBI HR= 1.25 [1.16, 1.36]; PCRS HR=1.67 [1.37,2.04]). Furthermore, we could determinate an inflection point for survival estimation by Barthel Index (BI 0-55/60-100*, p<0.001, HR=2.37 [1.59,3.53]), Katz Index (KI A-B*/C-G, p<0.001, HR=2.66 [1.80, 3.93], and Lawton-Brody Index (LBI 0-3/4-8*, p<0.001, HR=3.40 [2.09,5.25]). We reveal a correlation of the Charlson Index (p=0.002) and Katz Index (p=0.041) with number of readmissions for the study period. Conclusions: The geriatric scores analyzed are related to the cumulative survival rate after hip fracture surgery for more than 4 years, independently of other clinical and demographic factors. Katz Index in combination with Charlson Index could also be a potential predictor of the number of readmissions after surgery for hip fracture patients.

The All-on-Four Immediate Function Treatment Concept With NobelActive Implants: A Retrospective Study

2011 ◽  
Vol 37 (4) ◽  
pp. 431-445 ◽  
Author(s):  
Charles A Babbush ◽  
Gary T Kutsko ◽  
John Brokloff
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Cumulative Survival Rate ◽  
Treatment Concept ◽  
Single Center ◽  
Cumulative Survival ◽  
Prosthesis Survival ◽  
Immediate Function ◽  
Fixed Prosthesis

Abstract The All-on-Four treatment concept provides patients with an immediately loaded fixed prosthesis supported by 4 implants. This single-center retrospective study evaluated the concept while using the NobelActive implant (Nobel Biocare, Gothenburg, Sweden). Seven hundred eight implants placed in 165 subjects demonstrated a cumulative survival rate of 99.6% (99.3% in maxilla and 100% in the mandible) for up to 29 months of loading. The definitive prosthesis survival rate was 100%.

A New Approach to the All-on-Four Treatment Concept Using Narrow Platform NobelActive Implants

2013 ◽  
Vol 39 (3) ◽  
pp. 314-325 ◽  
Author(s):  
Charles A. Babbush ◽  
Ali Kanawati ◽  
John Brokloff
Keyword(s):  
Survival Rate ◽  
Standard Of Care ◽  
Cumulative Survival Rate ◽  
Implant Design ◽  
Treatment Concept ◽  
New Approach ◽  
Cumulative Survival ◽  
Implant Placement ◽  
Compromised Patients

Although a number of approaches to implant-supported restoration of severely atrophic maxillae and mandibles have been developed, most of these treatments are costly and protracted. An exception is the All-on-Four concept, which uses only 4 implants to support an acrylic, screw-retained provisional prosthesis delivered on the day of implant placement, followed by a definitive prosthesis approximately 4 months later. After the introduction of a new implant design in 2008, a new protocol was developed for provisionally treating patients with severely atrophic jaws using the All-on-Four concept and 3.5-mm-diameter implants. This article describes that protocol and reports on the results of 227 implants after 1 to 3 years of follow-up. The cumulative survival rate was 98.7% at the end of 3 years, with a 100% prosthetic survival rate. Combining the 3.5-mm-diameter NobelActive implants with the All-on-Four concept promises to become a new standard of care for severely compromised patients.

scholarly journals Cumulative survival rate of Astra Tech implants: a retrospective analysis

2011 ◽  
Vol 41 (2) ◽  
pp. 86 ◽  
Author(s):  
Jung-Soo Kim ◽  
Joo-Yeon Sohn ◽  
Jung-Chul Park ◽  
Ui-Won Jung ◽  
Chang-Sung Kim ◽  
...  
Keyword(s):  
Survival Rate ◽  
Retrospective Analysis ◽  
Cumulative Survival Rate ◽  
Cumulative Survival

scholarly journals Effect of Body Mass Index on the Prognosis of Liver Cirrhosis

2021 ◽  
Vol 8 ◽  
Author(s):  
Yue Yin ◽  
Yiling Li ◽  
Lichun Shao ◽  
Shanshan Yuan ◽  
Bang Liu ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Survival Rate ◽  
Normal Weight ◽  
Cumulative Survival Rate ◽  
Weight Group ◽  
Cumulative Survival ◽  
Normal Weight Group ◽  
Kaplan Meier ◽  
Significant Difference

Objective: At present, the association of body mass index (BMI) with the prognosis of liver cirrhosis is controversial. Our retrospective study aimed to evaluate the impact of BMI on the outcome of liver cirrhosis.Methods: In the first part, long-term death was evaluated in 436 patients with cirrhosis and without malignancy from our prospectively established single-center database. In the second part, in-hospital death was evaluated in 379 patients with cirrhosis and with acute gastrointestinal bleeding (AGIB) from our retrospective multicenter study. BMI was calculated and categorized as underweight (BMI &lt;18.5 kg/m2), normal weight (18.5 ≤ BMI &lt; 23.0 kg/m2), and overweight/obese (BMI ≥ 23.0 kg/m2).Results: In the first part, Kaplan–Meier curve analyses demonstrated a significantly higher cumulative survival rate in the overweight/obese group than the normal weight group (p = 0.047). Cox regression analyses demonstrated that overweight/obesity was significantly associated with decreased long-term mortality compared with the normal weight group [hazard ratio (HR) = 0.635; 95% CI: 0.405–0.998; p = 0.049] but not an independent predictor after adjusting for age, gender, and Child–Pugh score (HR = 0.758; 95%CI: 0.479–1.199; p = 0.236). In the second part, Kaplan–Meier curve analyses demonstrated no significant difference in the cumulative survival rate between the overweight/obese and the normal weight groups (p = 0.094). Cox regression analyses also demonstrated that overweight/obesity was not significantly associated with in-hospital mortality compared with normal weight group (HR = 0.349; 95%CI: 0.096-1.269; p = 0.110). In both of the two parts, the Kaplan–Meier curve analyses demonstrated no significant difference in the cumulative survival rate between underweight and normal weight groups.Conclusion: Overweight/obesity is modestly associated with long-term survival in patients with cirrhosis but not an independent prognostic predictor. There is little effect of overweight/obesity on the short-term survival of patients with cirrhosis and with AGIB.

scholarly journals Clinical Effects of Jiawei Danggui Beimu Kushen Pills in the Treatment of Prostate Cancer and Their Influence on the Expression of Serum Prostate Specific Antigen

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Haiyang Zhao ◽  
Zhiqiang Ren ◽  
Guangwen Wang
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Survival Rate ◽  
Cumulative Survival Rate ◽  
Control Group ◽  
Observation Group ◽  
Cumulative Survival ◽  
The Difference ◽  
Tcm Syndrome

Objective. To observe the clinical effects of Jiawei Danggui Beimu Kushen pills in treating prostate cancer and their influence on the expression of serum prostate specific antigen. Methods. A total of 234 prostate cancer patients were selected and randomly divided into observation group and control group, with 117 cases in each group. The control group was given oral bicalutamide tablets, while the observation group was treated with Jiawei Danggui Beimu Kushen pills on the basis of the control group. The treatment efficacy, IPSS score, TCM syndrome score, VAS score, quality-of-life score, and immune function of the two groups were compared before and after treatment. The serum PSA and f-PSA levels of patients before treatment and after 30 days, 90 days, and 180 days of treatment in the two groups were compared. The five-year cumulative survival rate and the incidence of adverse reactions were compared between the two groups. Results. After treatment, the total effective rate of the observation group was 88.03% (103/117), which was higher than that of the control group 69.23% (81/117); the difference was statistically significant ( P < 0.05 ). After treatment, the IPSS score, TCM syndrome score, and VAS score of the two groups were reduced, and those in the observation group were lower than those in the control group; the difference was statistically significant ( P < 0.05 ). After treatment, the quality-of-life scores of the two groups increased, and the observation group was higher than the control group; the difference was statistically significant ( P < 0.05 ). Before treatment, there was no significant difference in serum PSA levels and f-PSA levels when comparing between the two groups of patients ( P > 0.05 ). With the increase of treatment time, the two index levels of the two groups were gradually decreased. After 180 days of treatment, the two index levels of the two groups of patients were significantly lower than those before treatment, and the two index levels of the observation group were significantly lower than those of the control group; the difference was statistically significant ( P < 0.05 ). After treatment, the levels of IgM and IgA in the two groups were decreased, and the level of IgG was increased. The difference between the two groups in the levels of each index before and after treatment was statistically significant ( P < 0.05 ), and the difference between the two groups in the levels of each index after treatment was also statistically significant ( P < 0.05 ). The five-year cumulative survival rate of the observation group was 69.23%, and the five-year cumulative survival rate of the control group was 46.15% ( P < 0.05 ). There was no statistically significant difference between the two groups in the incidence of dizziness, fatigue, and gastrointestinal reactions ( P > 0.05 ), but the difference in the incidence of dysuria as well as dysuria and hematuria was statistically significant ( P < 0.05 ). Conclusion. Jiawei Danggui Beimu Kushen pills are effective in treating prostate cancer, which can effectively reduce the patients’ IPSS score and TCM syndrome scores, relieve the pain, and improve the quality of life of patients. They also have a potential role in regulating serum PSA levels, clearing tumor lesions, reducing postoperative complications, and improving related symptoms.

Sign in / Sign up

Export Citation Format

Share Document